Form 4: HilleVax Director Nanette Cocero Acquires 22,500 Stock Options

Director Nanette Cocero acquired 22,500 stock options in HilleVax, Inc. on June 6, 2024, as part of the non-employee director compensation program.

Summary

• Nanette Cocero, a director of HilleVax, Inc. [HLVX], acquired 22,500 stock options on June 6, 2024.
• The options were granted as part of the company's non-employee director compensation program.
• The exercise price of the stock options is $13.75.
• The options vest on the earlier of the first anniversary of the grant date (June 6, 2025) or the next annual meeting of stockholders, contingent on continued service on the board.
• The options expire on June 5, 2034.

Sentiment

Score: 7

Explanation: The document reflects a routine transaction (stock option grant) that is generally viewed positively as it aligns director interests with shareholders. There are no indications of negative sentiment.

Positives

• The grant of stock options aligns the director's interests with those of the shareholders.
• The vesting schedule incentivizes continued service on the board of directors.

Future Outlook

The vesting of the options is contingent upon continued service on the board, suggesting an expectation of ongoing involvement from the director.

Industry Context

Stock option grants are a common form of compensation for directors, aligning their interests with shareholders and incentivizing long-term value creation. This is a standard practice in the biotech industry to attract and retain experienced board members.

Comparison to Industry Standards

• Stock option grants to non-employee directors are a common practice across the biotechnology industry.
• Companies like Moderna and BioNTech also utilize stock options as part of their director compensation packages.
• The vesting schedules and exercise prices are typically structured to align with long-term value creation and shareholder interests.

Stakeholder Impact

• The stock option grant aligns the director's interests with those of the shareholders, potentially leading to decisions that benefit shareholder value.
• The vesting schedule incentivizes the director to remain engaged and contribute to the company's success.

Key Dates

Keywords

HilleVax, HLVX, stock options, director compensation, Nanette Cocero, Form 4, beneficial ownership